Beam Therapeutics [BEAM] vs Cg Oncology [CGON] Detailed Stock Comparison
Beam Therapeutics
NASDAQ
Loading...
Cg Oncology
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 17 vital metrics comparison: Beam Therapeutics wins in 5 metrics, Cg Oncology wins in 10 metrics, with 1 ties. Cg Oncology appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Beam Therapeutics | Cg Oncology | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.64 | -19.09 | Cg Oncology |
| Price-to-Book Ratio | 1.50 | 3.06 | Beam Therapeutics |
| Debt-to-Equity Ratio | 14.79 | 0.15 | Cg Oncology |
| PEG Ratio | 0.37 | -0.21 | Cg Oncology |
| EV/EBITDA | -1.36 | -8.41 | Cg Oncology |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | -1,419.22% | -28,546.10% | Beam Therapeutics |
| Return on Equity | -41.94% | -12.00% | Cg Oncology |
| Return on Assets (TTM) | -21.02% | -11.66% | Cg Oncology |
| Free Cash Flow (TTM) | $-356.19M | $-78.95M | Cg Oncology |
| 1-Year Return | -37.93% | -27.31% | Cg Oncology |
| Price-to-Sales Ratio (TTM) | 26.87 | 3,724.51 | Beam Therapeutics |
| Enterprise Value | $577.88M | $1.32B | Cg Oncology |
| EV/Revenue Ratio | 9.59 | 2,397.19 | Beam Therapeutics |
| Revenue per Share (TTM) | $1 | $0 | Beam Therapeutics |
| Earnings per Share (Diluted) | $-4.50 | $-1.78 | Cg Oncology |
| Beta (Stock Volatility) | 2.23 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Beam Therapeutics vs Cg Oncology Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Beam Therapeutics | 3.94% | -6.62% | -22.75% | -3.48% | -45.96% | -32.63% |
| Cg Oncology | 3.60% | 4.75% | 3.50% | 4.50% | 0.52% | -7.08% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Beam Therapeutics | -37.93% | -70.42% | -33.28% | -19.30% | -19.30% | -19.30% |
| Cg Oncology | -27.31% | -23.18% | -23.18% | -23.18% | -23.18% | -23.18% |
Performance & Financial Health Analysis: Beam Therapeutics vs Cg Oncology
| Metric | BEAM | CGON |
|---|---|---|
| Market Information | ||
| Market Cap | $1.62B | $2.05B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 2,701,040 | 517,967 |
| 90 Day Avg. Volume | 2,450,340 | 845,402 |
| Last Close | $16.64 | $26.92 |
| 52 Week Range | $13.52 - $35.25 | $14.80 - $40.47 |
| % from 52W High | -52.79% | -33.49% |
| All-Time High | $138.52 (Jun 28, 2021) | $50.23 (Feb 12, 2024) |
| % from All-Time High | -87.99% | -46.41% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.28% | -1.00% |
| Quarterly Earnings Growth | -0.28% | -1.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | -14.19% | -285.46% |
| Return on Equity (TTM) | -0.42% | -0.12% |
| Debt to Equity (MRQ) | 14.79 | 0.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $10.70 | $8.79 |
| Cash per Share (MRQ) | $11.71 | $8.67 |
| Operating Cash Flow (TTM) | $-344,824,000 | $-93,817,000 |
| Levered Free Cash Flow (TTM) | $-164,037,248 | $396.48M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Beam Therapeutics vs Cg Oncology
| Metric | BEAM | CGON |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.64 | -19.09 |
| Forward P/E | -3.36 | -15.12 |
| PEG Ratio | 0.37 | -0.21 |
| Price to Sales (TTM) | 26.87 | 3,724.51 |
| Price to Book (MRQ) | 1.50 | 3.06 |
| Market Capitalization | ||
| Market Capitalization | $1.62B | $2.05B |
| Enterprise Value | $577.88M | $1.32B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.59 | 2,397.19 |
| Enterprise to EBITDA | -1.36 | -8.41 |
| Risk & Other Metrics | ||
| Beta | 2.23 | N/A |
| Book Value per Share (MRQ) | $10.70 | $8.79 |
Financial Statements Comparison: Beam Therapeutics vs Cg Oncology
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BEAM | CGON |
|---|---|---|
| Revenue/Sales | $7.47M | $52,000 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | $98.82M | $27.47M |
| Operating Income (EBIT) | $-119.29M | $-42.20M |
| EBITDA | $-113.91M | $-42.18M |
| Pre-Tax Income | $-109.27M | $-34.45M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-109.27M | $-34.45M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BEAM | CGON |
|---|---|---|
| Cash & Equivalents | $527.91M | $41.47M |
| Total Current Assets | $1.25B | $701.19M |
| Total Current Liabilities | $141.55M | $22.64M |
| Long-Term Debt | $144.92M | $781,000 |
| Total Shareholders Equity | $1.12B | $704.76M |
| Retained Earnings | $-1.68B | $-252.43M |
| Property, Plant & Equipment | $176.23M | $1.30M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BEAM | CGON |
|---|---|---|
| Operating Cash Flow | $-81.45M | $-28.85M |
| Capital Expenditures | $-3.07M | $-16,000 |
| Free Cash Flow | $-106.95M | $-29.29M |
| Debt Repayment | $0 | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BEAM | CGON |
|---|---|---|
| Shares Short | 24.62M | 11.00M |
| Short Ratio | 10.11 | 11.27 |
| Short % of Float | 0.27% | 0.15% |
| Average Daily Volume (10 Day) | 2,701,040 | 517,967 |
| Average Daily Volume (90 Day) | 2,450,340 | 845,402 |
| Shares Outstanding | 83.63M | 76.15M |
| Float Shares | 87.02M | 61.28M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.06% | 1.12% |
Dividend Analysis & Yield Comparison: Beam Therapeutics vs Cg Oncology
| Metric | BEAM | CGON |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |